Only two reports with other concentrates describe this type of adverse reaction: a rash in a 4‐year‐old child (Type 3 VWD) treated by LTP with a 1:1 VWF/FVIII concentrate [16] and the development of VWF inhibitors in a 7‐year‐old girl (Type 3 VWD) during intensive treatment with a 2:1 VWF/FVIII concentrate [23]. This evidence concerns the gene VWF and von Willebrand disease (hereditary or acquired).